These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37651466)

  • 1. A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo.
    Taha TY; Suryawanshi RK; Chen IP; Correy GJ; McCavitt-Malvido M; O'Leary PC; Jogalekar MP; Diolaiti ME; Kimmerly GR; Tsou CL; Gascon R; Montano M; Martinez-Sobrido L; Krogan NJ; Ashworth A; Fraser JS; Ott M
    PLoS Pathog; 2023 Aug; 19(8):e1011614. PubMed ID: 37651466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis
    Taha TY; Suryawanshi RK; Chen IP; Correy GJ; O'Leary PC; Jogalekar MP; McCavitt-Malvido M; Diolaiti ME; Kimmerly GR; Tsou CL; Martinez-Sobrido L; Krogan NJ; Ashworth A; Fraser JS; Ott M
    bioRxiv; 2023 May; ():. PubMed ID: 37131711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Throughput Screening and Quantum Mechanics for Identifying Potent Inhibitors Against Mac1 Domain of SARS-CoV-2 Nsp3.
    Selvaraj C; Dinesh DC; Panwar U; Boura E; Singh SK
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1262-1270. PubMed ID: 33306471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique Mutations in the Murine Hepatitis Virus Macrodomain Differentially Attenuate Virus Replication, Indicating Multiple Roles for the Macrodomain in Coronavirus Replication.
    Voth LS; O'Connor JJ; Kerr CM; Doerger E; Schwarting N; Sperstad P; Johnson DK; Fehr AR
    J Virol; 2021 Jul; 95(15):e0076621. PubMed ID: 34011547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors.
    Brosey CA; Houl JH; Katsonis P; Balapiti-Modarage LPF; Bommagani S; Arvai A; Moiani D; Bacolla A; Link T; Warden LS; Lichtarge O; Jones DE; Ahmed Z; Tainer JA
    Prog Biophys Mol Biol; 2021 Aug; 163():171-186. PubMed ID: 33636189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An MHV macrodomain mutant predicted to lack ADP-ribose binding activity is severely attenuated, indicating multiple roles for the macrodomain in coronavirus replication.
    Voth LS; O'Connor JJ; Kerr CM; Doerger E; Schwarting N; Sperstad P; Johnson DK; Fehr AR
    bioRxiv; 2021 Mar; ():. PubMed ID: 33821264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice.
    Alhammad YM; Parthasarathy S; Ghimire R; Kerr CM; O'Connor JJ; Pfannenstiel JJ; Chanda D; Miller CA; Baumlin N; Salathe M; Unckless RL; Zuñiga S; Enjuanes L; More S; Channappanavar R; Fehr AR
    Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2302083120. PubMed ID: 37607224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase.
    Alhammad YMO; Kashipathy MM; Roy A; Gagné JP; McDonald P; Gao P; Nonfoux L; Battaile KP; Johnson DK; Holmstrom ED; Poirier GG; Lovell S; Fehr AR
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33158944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in mice.
    Alhammad YM; Parthasarathy S; Ghimire R; O'Connor JJ; Kerr CM; Pfannenstiel JJ; Chanda D; Miller CA; Unckless RL; Zuniga S; Enjuanes L; More S; Channappanavar R; Fehr AR
    bioRxiv; 2023 Apr; ():. PubMed ID: 37066301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3.
    Virdi RS; Bavisotto RV; Hopper NC; Vuksanovic N; Melkonian TR; Silvaggi NR; Frick DN
    SLAS Discov; 2020 Dec; 25(10):1162-1170. PubMed ID: 32981460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Roy A; Alhammad YM; McDonald P; Johnson DK; Zhuo J; Wazir S; Ferraris D; Lehtiö L; Leung AKL; Fehr AR
    Antiviral Res; 2022 Jul; 203():105344. PubMed ID: 35598780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SARS-CoV-2 conserved macrodomain is a mono-ADP-ribosylhydrolase.
    Alhammad YMO; Kashipathy MM; Roy A; Gagné JP; McDonald P; Gao P; Nonfoux L; Battaile KP; Johnson DK; Holmstrom ED; Poirier GG; Lovell S; Fehr AR
    bioRxiv; 2020 Oct; ():. PubMed ID: 32511412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species.
    Moustaqil M; Ollivier E; Chiu HP; Van Tol S; Rudolffi-Soto P; Stevens C; Bhumkar A; Hunter DJB; Freiberg AN; Jacques D; Lee B; Sierecki E; Gambin Y
    Emerg Microbes Infect; 2021 Dec; 10(1):178-195. PubMed ID: 33372854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrodomain Mac1 of SARS-CoV-2 Nonstructural Protein 3 Hydrolyzes Diverse ADP-ribosylated Substrates.
    Chea C; Lee DY; Kato J; Ishiwata-Endo H; Moss J
    bioRxiv; 2023 Feb; ():. PubMed ID: 36945431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligomeric assembly of the C-terminal and transmembrane region of SARS-CoV-2 nsp3.
    Babot M; Boulard Y; Agouda S; Pieri L; Fieulaine S; Bressanelli S; Gervais V
    J Virol; 2024 Apr; 98(4):e0157523. PubMed ID: 38483167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP12 is required to repress the replication of a Mac1 mutant coronavirus in a cell- and tissue-specific manner.
    Kerr CM; Parthasarathy S; Schwarting N; O'Connor JJ; Pfannenstiel JJ; Giri E; More S; Orozco RC; Fehr AR
    J Virol; 2023 Sep; 97(9):e0088523. PubMed ID: 37695054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based High-Throughput Virtual Screening and Molecular Dynamics Simulation for the Discovery of Novel SARS-CoV-2 NSP3 Mac1 Domain Inhibitors.
    Yazdani B; Sirous H; Brogi S; Calderone V
    Viruses; 2023 Nov; 15(12):. PubMed ID: 38140532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Roy A; Alhammad YM; McDonald P; Johnson DK; Zhuo J; Wazir S; Ferraris D; Lehtiö L; Leung AKL; Fehr AR
    bioRxiv; 2022 Mar; ():. PubMed ID: 35262075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation of a highly conserved isoleucine residue in loop 2 of several 𝛽-coronavirus macrodomains indicates that enhanced ADP-ribose binding is detrimental to infection.
    Kerr CM; Pfannenstiel JJ; Alhammad YM; O'Connor JJ; Ghimire R; Shrestha R; Khattabi R; Saenjamsai P; Parthasarathy S; McDonald PR; Gao P; Johnson DK; More S; Roy A; Channappanavar R; Fehr AR
    bioRxiv; 2024 Jul; ():. PubMed ID: 38260573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors.
    O'Connor JJ; Ferraris D; Fehr AR
    Pathogens; 2023 Oct; 12(10):. PubMed ID: 37887737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.